Overview

A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the efficacy and safety of enzastaurin in participants with Cutaneous T-Cell Lymphoma (CTCL) who failed prior therapies.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company